Vector BioMed Selected As Top Lentiviral Vector Design And Manufacturing Company

Life Sciences Review recognizes the pure-play lentiviral vector company’s work to help Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients.

Gaithersburg, MD -- Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review. The recognition highlights the company’s specialized lentiviral vector expertise and its work helping healthcare providers around the world develop and deliver advanced cell and gene therapies closer to where patients live.

Vector BioMed is also recognized in Life Sciences Review’s Top CDMO in APAC, a list that includes WuXi AppTec, LOTTE BIOLOGICS and AsymBio.

Founded in 2023 by veterans of the team behind the first lentiviral CAR-T therapy to reach patients, Vector BioMed has served more than 40 clients, developing vectors for therapies targeting leukemia, lymphoma and multiple myeloma. Unlike contract manufacturers that work across many technologies, Vector BioMed focuses exclusively on lentiviral vectors. Its proprietary LENTIVERSE™ platform is designed to reduce the technical and financial barriers to bringing new treatments to patients.

“We felt it was very important to create a company that really focuses on creating processes that lead to more efficient production and ultimately reducing the cost,” said Boro Dropulić, PhD, MBA, Vector BioMed CEO, in the Life Sciences Review profile.

Expanding Access to Advanced Therapies Worldwide

Vector BioMed works to make advanced therapies available in regions where high costs, limited manufacturing infrastructure and a shortage of specialized expertise have restricted treatment. Through partnerships and collaborations across the Asia-Pacific region, the company helps healthcare providers manufacture cell therapies locally rather than relying only on centralized facilities.

In India, this model supports efforts to expand CAR-T treatment at Muni Seva Ashram in Vadodara, a treatment center serving economically disadvantaged patients.

“Proximity to treatment is the primary factor in determining who gets treated,” said Michael Kadan, PhD, MBA, Vector BioMed COO, in the Life Sciences Review profile.

By supporting standardized manufacturing procedures and widely available equipment, Vector BioMed helps clinical partners build local treatment capabilities. Its team also gives local healthcare teams direct access to lentiviral vector scientists and process engineers, who help them manufacture cell therapies consistently and build the expertise to sustain these programs.

“Not only are we focused on the cost, but also the quality,” said Indraneel Ghosh, PhD, Vector BioMed’s Director of Business Development, Asia, in the Life Sciences Review profile.

Purpose-Built Technology to Bring Treatments Closer to Patients

Vector BioMed’s LENTIVERSE™ platform is built to fit into existing facilities and workflows. LaunchSuite gives local teams ready-to-deploy lentiviral vectors, supporting documentation and standardized cell manufacturing processes for established CAR-T targets, so treatment can happen where patients receive care. VectorCraft provides custom lentiviral vector development and manufacturing for therapies at earlier stages. The company typically advances a gene sequence to a GMP-manufactured vector in less than 12 months.

Global Recognition Driven by Innovation and Patient Access

Life Sciences Review selected Vector BioMed through a multistage evaluation that included subscriber nominations, editorial research and an assessment of the company’s capabilities, market relevance and industry impact by an editorial advisory board of industry peers and analysts. Details are available in the publication’s methodology.

The recognition reflects Vector BioMed’s exclusive focus on lentiviral vectors, its growing relationships across the Asia-Pacific region and practical solutions that help healthcare providers overcome the technical, financial and infrastructure challenges of delivering advanced therapies.

It also reinforces Vector BioMed’s mission to make advanced cell and gene therapies more accessible worldwide by equipping local healthcare teams with the technology, processes and scientific expertise needed to bring new treatments to patients.

To read about Vector BioMed’s award, visit Life Sciences Review.

About Vector BioMed

Vector BioMed is a CVDMO dedicated solely to lentiviral vector development and manufacturing. Its LENTIVERSE™ platform offers both custom VectorCraft solutions and rapid formats in LaunchSuite, creating a precise fit for any development stage or budget. Unlike broad-spectrum CDMOs, Vector BioMed delivers specialized expertise, risk-free contracts and reproducible quality that minimize variability and accelerate timelines. From early-stage development through commercial-scale manufacturing, Vector BioMed acts as a true scientific partner, not just a vendor, helping innovators bring therapies to patients faster, at lower cost and with zero surprises.